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SpondyloarthropathiesApremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic in-
ﬂammatory disorders, and has shown efﬁcacy in psoriasis, psoriatic arthropathies, and Behçet's syndrome. In
March 2014, the US Food and Drug Administration approved apremilast for the treatment of adult patients
with active psoriatic arthritis. The properties of apremilast were evaluated to determine its speciﬁcity, effects
on intracellular signaling, gene and protein expression, and in vivo pharmacology using models of innate and
adaptive immunity. Apremilast inhibited PDE4 isoforms from all four sub-families (A1A, B1, B2, C1, and D2),
with IC50 values in the range of 10 to 100 nM. Apremilast did not signiﬁcantly inhibit other PDEs, kinases, en-
zymes, or receptors. While both apremilast and thalidomide share a phthalimide ring structure, apremilast
lacks the glutarimide ring and thus fails to bind to cereblon, the target of thalidomide action. In monocytes and
T cells, apremilast elevated intracellular cAMP and induced phosphorylation of the protein kinase A substrates
CREB and activating transcription factor-1 while inhibiting NF-κB transcriptional activity, resulting in both up-
and down-regulation of several genes induced via TLR4. Apremilast reduced interferon-α production by
plasmacytoid dendritic cells and inhibited T-cell cytokine production, but had little effect on B-cell immunoglob-
ulin secretion. In a transgenic T-cell and B-cell transfer murine model, apremilast (5 mg/kg/day p.o.) did not
affect clonal expansion of either T or B cells and had little or no effect on their expression of activation
markers. The effect of apremilast on innate immunity was tested in the ferret lung neutrophilia model,
which allows monitoring of the known PDE4 inhibitor gastrointestinal side effects (nausea and vomiting).
Apremilast signiﬁcantly inhibited lung neutrophilia at 1 mg/kg, but did not induce signiﬁcant emetic re-
ﬂexes at doses b30 mg/kg. Overall, the pharmacological effects of apremilast are consistent with those of
a targeted PDE4 inhibitor, with selective effects on innate immune responses and a wide therapeutic
index compared to its gastrointestinal side effects.
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Inﬂammatory conditions, such as psoriasis and psoriatic arthritis
(PsA), are related to a dysregulated immune system governed by a
pro-inﬂammatory cytokine network [1–3]. The network of pro-
inﬂammatory mediators that drive psoriasis and PsA are released by a
variety of cell types, including innate or adaptive immune cells, and
resident non-immune cells [1–3]. The cyclic nucleotides cAMP and
cGMP are naturally occurring intracellular secondary messengers
critical to translating extracellular stimuli into intracellular signals that
control gene expression, allowing the cell to interact with its environ-
ment and regulate broader physiological processes, including those
involved in inﬂammation [4]. In the presence of inﬂammatory extracel-
lular signals, G-protein-coupled receptors bindwith a variety of ligands,
such as leukotrienes, prostaglandins, chemokines, and histamine, and
activate adenylyl cyclase, which promotes increased production of
cAMP [5]. cAMP interacts with effector proteins such as protein kinase
A (PKA) and exchange proteins activated by cAMP (Epac) to elicit
changes in gene expression [6]. PKA activation results in phosphoryla-
tion of the cAMP-responsive binding element family of transcription
factors, including cAMP responsive element binding protein (CREB)
and activating transcription factor-1 (ATF-1), while inhibiting activity
of other promoters such as nuclear factor kappa B (NF-κB) [3,7,8].
Such effects on CREB, ATF-1, and NF-κB cause decreased mRNA expres-
sion of cytokines and other inﬂammatorymediators aswell as increased
expression of anti-inﬂammatory signals [5,8]. In this way, cAMP signal-
ing helps to maintain immune homeostasis by modulating the produc-
tion of pro-inﬂammatory and anti-inﬂammatory mediators [5]. When
intracellular cAMP concentrations are high, inﬂammatory signaling is
dampened; likewise, when cAMP levels are depleted, expression of
inﬂammatory mediators increases. By modulating the levels of inﬂam-
matory and anti-inﬂammatory mediators expressed and released by
immune cells, cAMP is one component in a cascade that determines
recruitment of immune responses both in the local milieu and through-
out the body.
Intracellular levels of cAMP are tightly controlled by adenylyl
cyclase, which promotes cAMP formation, and by cyclic nucleotide
phosphodiesterases (PDEs), which are the only means of degrading
cAMP, via enzymatic hydrolysis. There are 11 distinct families of cAMP
and/or cGMP-selective PDEs expressed in mammalian species (PDE1–
11), each containing a conserved catalytic domain in the carboxy-
terminal portion of the enzyme, plus amino-terminal subdomains that
are important for subcellular localization, and for interactions with sig-
nalingmolecules andmolecular scaffolds [9].While certain PDEs specif-
ically hydrolyze cAMP (PDE4, PDE7, and PDE8), or speciﬁcally hydrolyze
cGMP (PDE5, PDE6, and PDE9), others hydrolyze both cAMP and cGMP
(PDE1, PDE2, PDE3, PDE10, and PDE11) [9]. In most mammalian cells,
PDE3 and PDE4 predominantly hydrolyze cAMP [9]. Unlike PDE3,
PDE4 is cAMP-speciﬁc and the dominant PDE in inﬂammatory cells [3,
10]. PDE4 is also expressed in structural cell types involved in psoriasis,
such as keratinocytes, vascular endothelium, and synovium [11]. The
PDE4 isoenzyme family is encoded by four genes (PDE4A, PDE4B,
PDE4C, and PDE4D) and consists of more than 20 distinct isoforms,
each with a unique N-terminal region, created by mRNA splicing and
different promoters [4,12]. PDE4 isoforms are categorized as long,
short, or super short depending on the presence and number of up-
stream conserved regions, highly conserved domains located between
the catalytic domain and the N-terminal region; dead-short isoforms
are those containing no upstream conserved regions and a truncated,
nonfunctional catalytic domain [13]. In linewith the structural diversity
of the PDE4 family, the unique N-terminal region of each PDE4 isoform
allows each to be sequestered by speciﬁc protein partners within
sub-regions of the cell [12]. PDE4 inhibition elevates intracellular
cAMP levels, which results in down-regulation of the inﬂammatory re-
sponses by reducing the expression of tumor necrosis factor (TNF)-α,
interleukin (IL)-23, and other pro-inﬂammatory cytokines, whileincreasing anti-inﬂammatory cytokines, such as IL-10 [3,14]. Therefore,
PDE4 is of interest as a therapeutic target in the treatment of chronic
inﬂammatory conditions [14,15]. Currently marketed PDE4 inhibitors
include apremilast (Otezla®, Celgene Corporation, Summit, New Jersey)
[16], approved in the United States for the treatment of adult
patients with active PsA, and roﬂumilast (Daliresp®, Forest
Pharmaceuticals, St. Louis, Missouri) [17] for the treatment of chronic
obstructive pulmonary disorder.
Apremilast is an oral small molecule inhibitor of PDE4 [11,15,18]
which has been shown to be effective andwell tolerated in clinical trials
in psoriasis (phase III), PsA (phase III), and Behçet's disease (phase II).
Targeted inhibition of PDE4 results in partial inhibition of pro-
inﬂammatory mediator production, such as TNF-α, interferon-γ, and
IL-23, and increases in anti-inﬂammatory mediator production, such
as IL-10 [3,15,19], which in turn results in reduced inﬁltration of im-
mune cells and changes in resident cells of the skin and joints [11,15,
19,20]. In vitro, apremilast signiﬁcantly reduced expression of TNF-α,
IL-7, and the matrix metalloproteinases MMP1, MMP3, MMP13, and
MMP14 by synoviocytes derived from patients with rheumatoid
arthritis [19,21,22]. In other cell culture models, apremilast inhibited
the differentiation of osteoclasts, as well as their bone-resorbing activi-
ty, and reduced the production of RANKL by osteoblasts [23]. In patients
with severe plaque psoriasis, apremilast reduced inﬁltration of myeloid
dendritic cells (DCs) into the dermis and epidermis and inducible nitric
oxide synthase mRNA expression; epidermal thickness was reduced by
approximately 20% over 29 days [20]. A subsequent study in recalcitrant
plaque psoriasis demonstrated that apremilast reduced epidermal and
dermal inﬁltration of myeloid DCs, T cells, and natural killer (NK) cells,
and inhibited the expression of genes in the Th1, Th17, and Th22 path-
ways in the psoriatic skin lesions, including IL-12/IL-23p40, IL-23p19,
IL-17A, and IL-22 [24]. Phase II and phase III studies have demonstrated
the clinical efﬁcacy of apremilast in the treatment of patientswith active
PsA and moderate to severe plaque psoriasis, and phase II studies have
demonstrated the efﬁcacy of apremilast for patients with Behçet's
disease [25–33].
The current analyses studied the pharmacodynamic properties of
apremilast, with three speciﬁc aims: 1) ascertain the selectivity of
apremilast by determining whether it binds to targets other than
PDE4 in the cell; 2) deﬁne which signaling pathways downstream of
PDE4 aremodulated by apremilast; and 3) identify the repertoire of im-
mune cells affected by the drug. Our data show that apremilast has no
identiﬁed binding targets other than PDE4 and mediates its effects in
monocytes and T cells via PKA and NF-κB pathways. Apremilast modu-
lates gene expression in monocytes, reduces interferon-α production
induced by TLR9 signaling in plasmacytoid DCs, and inhibits cytokine
production by T cells, but has little effect on immunoglobulin secretion
by B cells in vitro. To assess its impact on the adaptive immune re-
sponse, apremilast was tested in an antigen-speciﬁc transgenic mouse
model of T- and B-cell clonal expansion, activation marker expression,
and immunoglobulin production. Using the ferret as both a model of
an innate inﬂammatory response, and for the gastrointestinal side
effects of PDE4 inhibition, a therapeutic index was measured in vivo.2. Material and methods
2.1. Materials
Celgene Corporation (Summit, New Jersey) synthesized
apremilast (CC-10004 or [S]-N-[2-[1-3-ethoxy-4-methoxyphenyl]-2-
methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acet-
amide) and other PDE4 inhibitors, as well as thalidomide, lenalidomide
(CC-5013), and pomalidomide (CC-4047). Forskolin was obtained from
Sigma (St. Louis, Missouri) and dimethyl sulfoxide (DMSO), used
to generate stock solutions, was obtained from Research Organics
(Cleveland, Ohio).
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2.2.1. PDE selectivity
Apremilast (10 μΜ) PDE enzyme speciﬁcity was assessed against re-
combinant human PDEs 1A, 1C, 2A, 3A, 3B, 4A1A, 4B1, 4B2, 4C1, 4D2,
5A1, 7A, 7B, 8A1, 9A2, 10A1, and 11A4 using IMAP™ TR-FRET Screening
Express with Progressive Binding Kit (Molecular Devices, Sunnyvale,
California). The PDE4 isoforms examined included long isoforms
PDE44B1 [34] and PDE44C1 [35], the short isoforms PDE4B2 [36] and
PDE4D2 [37], and the super-short isoformPDE4A1A [38]. The enzymatic
reactions were conducted at room temperature for 1 h in a 50 μL
mixture of IMAP reaction buffer, 100 nM FAM-cAMP, or 100 nM FAM-
cGMP, test compound, and a PDE enzyme. Fluorescence intensity was
measured at an excitation of 485 nm and an emission of 528 nm using
a BioTek Synergy™ 2 microplate reader and converted to ﬂuorescence
polarization (FP) using Gen5 software. The highest value of FP in each
data set was deﬁned as 100% activity, and the percent binding activity
in the presence of compound was calculated by (FP in presence of com-
pound− FP in absence of PDE enzyme and compound) / (highest FP−
FP in presence of compound) × 100%. PDE6 enzymatic activity was
measured enzymatically using PDE6 isolated from bovine retinal rod
outer segments at 100 μM cGMP for 20 min at 25 °C (MDS Pharma,
Bothell, Washington).
The kinase inhibition proﬁle of 10 μM apremilast was determined
using the SelectScreen® Proﬁling Service (Invitrogen, Carlsbad,
California), which included 255 kinases. Signiﬁcant kinase inhibition
was considered to be reproducible inhibition of 50% or more at 10 μM.
The effects of 10 μM apremilast on binding to 68 cell surface
receptors and for inhibition of 17 enzymes were tested (Cerep Diversity
Proﬁle, Cerep SA, Poitiers, France, and Cerep, Inc., Seattle, Washington).
Receptors tested include adenosine, adrenergic, angiotensin, benzodiaze-
pine, bradykinin, cannabinoid, cholecystokinin, corticotrophin-releasing
factor, dopamine, endothelin, γ-aminobutyric acid, α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid, kainite, N-methyl-D-aspartate, hista-
mine, imidazoline, leukotriene, melanocortin, muscarinic, neurokinin,
neuropeptide Y, opioid, nociceptin, phencyclidine, purinergic, serotonin,
glucocorticoid, estrogen, progesterone, androgen, thyrotropin-releasing
hormone, and vasopressin, and ion channels, including calcium, sodium,
chloride, and potassium, transporters including norepinephrine, dopa-
mine, γ-aminobutyric acid, choline, and serotonin. Enzymes included
phosphodiesterases, adenylyl cyclase, guanylyl cyclase, protein kinase C,
acetylcholinesterase, catechol-O-methyl transferase, γ-aminobutyric
acid transaminase, monoamine oxidases, phenylethanolamine-N-
methyl transferase, tyrosine hydroxylase, and ATPase. Receptor binding
by a speciﬁc ligand was deﬁned as the difference between the total bind-
ing and the nonspeciﬁc binding determined in the presence of an excess
of unlabeled ligand. Resultswere expressed as a percent inhibition of con-
trol speciﬁc binding or as a percent variation of control values obtained in
the presence of apremilast.
Competition studies with cereblon binding to thalidomide-analog
afﬁnity beads were performed using varying concentrations of
apremilast, lenalidomide (positive control), and DMSO (control) prein-
cubated (15min at room temperature) with human U266multiple my-
eloma cell extract (American Type Cell Culture, Manassas, Virginia)
containing cereblon. Thalidomide analog-coupled beads were prepared
using ferrite glycidyl methacrylate afﬁnity beads, as described by Ito
et al. [39]. Beads were added to protein extracts, and the samples
were rotated for 2 h at 4 °C and then washed three times. The bound
proteins were eluted with sodium dodecyl sulfate polyacrylamide gel
electrophoresis sample buffer and cereblon binding was quantiﬁed by
two independent immunoblots using the anti-cereblon monoclonal
antibody CRBN 65–76 (1:10,000). Cereblon signal density relative to
control density was graphed using PrismGraph nonlinear regression
analysis set at log inhibitor versus response with a variable slope and
bottom constraint set to zero. The PrismGraph program calculated
standard error of the mean for each compound concentration point.2.2.2. cAMP elevation
Human peripheral blood mononuclear cells (PBMCs) were isolated
by Ficoll gradient from source leukocytes (buffy coat) and plated in
96-well plates at 1 × 106 cells per well in RPMI-1640. The cells were
pre-treated with compounds at 100, 10, 1, 0.1, 0.01, 0.001, 0.0001, and
0 μM in a ﬁnal concentration of 2% DMSO in duplicate at 37 °C in a
humidiﬁed incubator at 5% CO2 for 1 h. The cells were then stimulated
with prostaglandin E2 (10 μM) (Sigma) for 1 h. The cells were lysed
with HCl, 0.1 N ﬁnal concentration to inhibit PDE activity, and the plates
were frozen at−20 °C. The cAMP produced wasmeasured using cAMP
(low pH) immunoassay kit (R&D Systems, Minneapolis, Minnesota).
cAMP levels were normalized to the level induced by prostaglandin E2
in the presence of 100 μM rolipram.
2.2.3. LPS-induced TNF-α production
PBMCproduction of TNF-α induced by lipopolysaccharide (LPS)was
performed as previously described [15].
2.2.4. Plasmacytoid DC interferon-α production
The effect of apremilast on interferon-α production by plasmacytoid
DCs was assessed in PBMCs stimulated via TLR9. PBMCs were isolated
from donor-collected peripheral blood. Cells were pretreated with
apremilast for 1 h before stimulation with the TLR9 agonist CpG-A
oligodeoxynucleotide 2216 (InvivoGen, San Diego, California) over
16 h. Using an enzyme-linked immunosorbent assay (ELISA), the opti-
mal concentration of CpG-A oligodeoxynucleotide 2216 was identiﬁed
as 1 μM for interferon-α production from PBMCs (109 pg/mL). At the
end of the treatment period, supernatant was collected for analysis of
interferon-α production using ELISA (Pierce Chemical Company,
Rockford, Maryland). The half-maximal inhibitory concentration (IC50)
was calculated from the non-linear regression, sigmoidal dose response
curves constraining the minimum of 0% and maximum of 100%
(GraphPad Prism v4.0, San Diego, California).
2.2.5. B-cell immunoglobulin production
The effects of apremilast on B-cell differentiation were studied in
PBMCs and compared with pomalidomide. B cells were isolated from
PBMCs and activated with a cocktail of IL-2, IL-10, IL-15, CD40 ligand/
TNFSF5/histidine-tagged polyHistidine mouse IgG1 antibody,
and oligodeoxynucleotide 2006-human TLR9 ligand. Apremilast,
pomalidomide, or DMSO was added to each well of a six-well ﬂat-
bottom plate and incubated for 4 days at 37 °C. Cells were harvested
and washed with phosphate-buffered saline (PBS), and a fresh B-cell
cocktail of IL-2, IL-10, IL-15, and IL-6 was added to the cells. Test com-
pounds were again added and incubated for 3 days at 37 °C. On Day 7,
supernatants were harvested and analyzed by ELISA for IgG and IgM
production (ZeptoMetrix Corporation, Buffalo, New York). IC50 was cal-
culated from the non-linear regression, sigmoidal dose response curves
constraining the minimum of 0% and maximum of 100% (GraphPad
Prism v5.0). Results were expressed as the percent inhibition relative
to control DMSO values or as present expression calculated relative to
the DMSO control (100% expression).
2.2.6. T-cell cytokine production
T cells were isolated from buffy coat by negative selection using the
RosetteSep T Cell Enrichment Cocktail (STEMCELL Technologies,
Vancouver, British Columbia, Canada) according to manufacturer's
procedures. All 96-well plates were pre-coated with 3 μg/mL anti-
human CD3 antibody OKT3 clone (eBioscience, Cat# 16-0037-85) in
100 μL 1× PBS for 4 h at 37 °C. The plates were washed three times
with RPMI-1640 Complete Media before the T-cell assay. The T cells
were then plated in anti-CD3-pre-coated plates at a density of
2.5 × 105 cells/well in 180 μL RPMI-1640 Complete Media. The cells
were treatedwith 20 μL 10× compounds. The ﬁnal DMSO concentration
was 0.25%. The plates were incubated for 48 h at 37 °C, 5% CO2. After
48 h, the supernatants were harvested and tested by a multiplex
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Chemokine 12-Plex Kit (Cat# MPXHCYTO-60K-12, Millipore, Billerica,
Massachusetts) and analyzed on a Luminex IS100 instrument
(Millipore).
2.2.7. Gene expression in monocytes
The effects of apremilast (1 μM) on gene expression were studied in
a gene chip analysis and compared with the thalidomide analogs
lenalidomide (10 μM) and pomalidomide (1 μM), the PDE4 inhibitors
roﬂumilast (0.1 nM) and cilomilast (1 μM), and the c-Jun N-terminal in-
hibitor CC-225400 (10 μM). CD14+ monocytes were isolated from
PBMCs from four donors, and theRNAwaspooled. Cellswere pretreated
with compounds for 1 h and then stimulated with 50 ng/mL LPS for 6 h.
GeneChip Human Genome U133A array (Affymetrix, Santa Clara,
California) encoding probes, representing approximately 13,000 unique
human genes, were used. Gene expression datawere analyzed and gene
ontology pathways were compared using NextBio software (Illumina,
Inc., San Diego, California). Based on results, a set of the most highly
apremilast-modulated genes were chosen for conﬁrmatory studies
using real-time polymerase chain reaction analysis of mRNA expressed
in LPS-stimulated human monocytes and human PBMCs. Statistical
analysis was performed using two-way analysis of variance (ANOVA)
Bonferroni post-test versus control.
2.2.8. Intracellular signaling
The intracellular mechanism of action of apremilast on the PKA and
NF-κB pathwayswas studied in Jurkat T-cell leukemia and THP-1mono-
cytic leukemia cell lines (American Type Cell Culture). Cells were cul-
tured at 10 million cells per dish in 10 × 10 cm tissue culture dishes in
10 mL Roswell Park Culture Medium-1640 Media (Mediatech Inc., Ma-
nassas, Virginia) and supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin.
The next day, the cells were treated with 0.1% DMSO (control), 0.1, 1,
and 10 μM apremilast, with and without the adenylyl cyclase activator
forskolin (10 μM), or 1, 0.1, and 0.01 μM roﬂumilast. After 30 min, the
cells were washed twice in ice-cold PBS, then lysed for 10 min in
200 μL/sample pre-chilled 1× RIPA Buffer (Thermo Fisher, Waltham,
Massachusetts) supplemented with 1× protease and phosphatase in-
hibitors. The lysates were vortexed for 30 s and centrifuged in a
microcentrifuge at maximum speed (16,100 ×g) for 10 min at 4 °C.
The BCA Assay Kit (Thermo Fisher) was used according to
manufacturer's procedures to measure protein concentration.
To determine NF-κB nuclear localization, Jurkat T cells and THP-1
monocytic cells were incubated under the same conditions with
10 μM IκB kinase inhibitor VII (Calbiochem, Billerica, Massachusetts).
After a 1-hour incubation at 37 °C, Jurkat T cells were stimulated with
20 ng/mL recombinant human TNF-α (R&D Systems), and THP-1 cells
were stimulated with 1 μg/mL LPS Escherichia coli 0127:B8 (Sigma) for
an additional hour. The cells were centrifuged at 1200 RPM (290 ×g)
for 10 min and washed twice with cold 1× PBS (Mediatech Inc.). Cyto-
plasmic and nuclear proteins were isolated using the NE-PER Cytoplas-
mic and Nuclear Protein Extraction Kit (Thermo Fisher), following the
manufacturer's procedure for 20 μL packed cell volume, and the protein
concentration was measured using the BCA Assay Kit, as described
above.
Western blot was used to measure the phosphorylation of the PKA
substrate CREB at Ser133 and NF-κB p65. The lysates were run on 10%
Tris–HCl pre-cast gels (Bio-Rad, Hercules, California) at 50 μg protein
per lane at 160 V until the protein of interest reached two thirds of
the gel. The proteins were transferred to nitrocellulose membrane
(Invitrogen, Grand Island, New York) and run at 100 V for 3 h on ice.
After 3 h, the membranes were blocked using Odyssey Blocking Buffer
(LI-COR, Lincoln, Nebraska) for 1 h at room temperature on a shaker
and then they were probed with either phospho-CREB Ser122 Rabbit
Antibody or NF-κB p65Rabbit Antibody (Cell Signaling, Danvers,Massa-
chusetts) and incubated overnight at 4 °Cwith gentle shaking. The nextday, the membranes were washed and LI-COR secondary antibody goat
anti-rabbit IRDye 680 LT (1:20,000) was added. After incubation and
washing, the blots were analyzed on the LI-COR Odyssey instrument.
The blots were stripped and re-probed with β-actin (1:20,000, Clone
AC-15 produced in mouse; Sigma), incubated for 1 h on a shaker, and
then washed. Secondary antibody goat anti-mouse IRDye 800 CW
(LI-COR) was added and incubated for 30 min with gentle shaking.
After washing, the blots were analyzed on the LI-COR Odyssey Imaging
System. Densitometry was performed, and each band was normalized
to the corresponding β-actin band.
Jurkat T cells and THP-1 cells were plated at a density of
100,000 cells per well in 100 μL RPMI-1640 Media and incubated over-
night at 37 °C, 5% CO2. The wells were transfected with Superfect:DNA
complex and incubated for 10 min at room temperature. After 10 min,
the master mix of Opti-MEM Medium, Superfect reagent, and plasmid
DNA stockwas added to the plate, whichwas subsequently mixed, cov-
ered, and incubated for 24 h at 37 °C. The next day, 10× compound so-
lutions and 10× inducing controls were prepared. The cells were
pretreated with 10 μL of 10× titrated compounds and 0.1, 1, and
10 μM apremilast. After 1 h, Jurkat T cells were stimulated with 10 μL
of 10× recombinant human TNF-α, and THP-1 cells were stimulated
with 10 μL of 10× LPS and then incubated for 6 h at 37 °C. Luciferase ac-
tivity was analyzed using the One-Glo™ Luciferase Assay System
(Promega, Madison,Wisconsin) according to themanufacturer's proce-
dures. Each 100 μL sample was placed in an Eppendorf tube and ana-
lyzed in duplicate on the single tube luminometer (Turner Designs
TD-20/20) in standard mode.
2.2.9. Transgenic T- and B-cell model
Antigen-speciﬁc adaptive immune responseswere studied using the
transgenic mouse T- and B-cell transfer model with male and female
IgHb mice (University of Glasgow), as previously described [40]. This
study was conducted before the enactment of the EU Directive 2010/
63/EU for animal experiments. The CD4+ T cells of the DO11.10 T-cell
receptor-transgenic mice are speciﬁc for a chicken ovalbumin (OVA)
peptide (amino acid residues 323–339) in the context of the MHCII
molecule I-Ad and can be identiﬁed using the clonotypic monoclonal
antibody KJ1–26 (referred to as KJ+ T cells). MD4 B-cell receptor-
transgenic mice, which are speciﬁc for hen egg lysozyme (HEL), can
be identiﬁed using an antibody speciﬁc for the IgMa allotype (referred
to as MD4+ B cells). During acclimation and after dosing, animals
were housed in groups of 10 mice maximum in polypropylene cages
(37.5 × 21 × 18 cm) ﬁtted with solid bottoms and ﬁlled with wood
shavings as bedding material. Mice were housed at 20 °C to 24 °C at
30% to 70% relative humidity and a 12:12 h light:dark cycle, and were
provided a commercial high-fat rodent diet ad libitum and free
access to drinking water, supplied to each cage via polyethylene bottles
with stainless steel sipper tubes. Groups of 30 mice were randomly
assigned to each of the four treatment regimens. On Day−1, antigen-
speciﬁc transgenic T and B cells were injected intravenously via the
tail vein using 3 × 106 KJ+ T cells and 3.5 × 106 MD4+ B cells. On
Day 0, mice were immunized by subcutaneous injection of 130 μg
OVA-HEL/Complete Freund's Adjuvant emulsion (per mouse). Mice
were treated with apremilast (5 mg/kg) or the vehicle (0.5% carboxy-
methylcellulose/0.25% Tween 80) once daily commencing on Day−1.
At the end of the study, surviving animals were euthanized by cervical
dislocation. On Day 2, sampling of inguinal, axillary, brachial lymph
nodes was conducted using ﬁve mice per time point for ﬂow cytometry
to count KJ+ T cells and MD4+ B cells; for CD69, CD25 (IL-2 receptor),
and CD62L (L-selectin) expression on the KJ+ T cells; and for CD40,
CD80, CD86, and MHCII expression on IgMa+ B cells.
2.2.10. Ferret lung neutrophilia and emesis model
Male ferrets (Mustela pulorius furo, weighing 1 to 2 kg) were
supplied either by Bury Green Farm (Hertfordshire, UK) or Misay Con-
sultancy (Hampshire, UK). This study was conducted before the
Fig. 1. Effect of apremilast on PDE enzyme activity. Apremilast (10 μM) was added to
phosphodiesterases, and enzymatic activity was measured, as described in the Material
andmethods section. Enzymatic reactionswere carried out in 100nMcAMPas a substrate,
except for PDE5A1 and PDE9A2 (100 nM cGMP) and retinal rod PDE6 (100 μM). Data are
shown as the mean with the standard deviation from assays performed in duplicate.
2020 P.H. Schafer et al. / Cellular Signalling 26 (2014) 2016–2029enactment of the EU Directive 2010/63/EU for animal experiments.
Following transport, the animals were allowed to acclimatize in the
holding rooms for ≥7 days. Meals comprised SDS diet C pelleted food
given ad lib withWhiskas cat food given three times per week. Pasteur-
ized animal grade drinking water was changed daily. PDE4 inhibitors
were administered orally (p.o.) at doses of 0.1 to 30 mg/kg (apremilast)
or 1 to 10 mg/kg (cilomilast). Ferrets were fasted overnight but allowed
free access towater. The animalswere orally dosedwith vehicle or PDE4
inhibitor using a 15 cmdosing needle that was passed down the back of
the throat into the esophagus. After dosing, the animals were returned
to holding cages ﬁtted with acrylic doors to allow observation and
given free access towater. After dosing, the animalswere constantly ob-
served and any emesis or behavioral changes were recorded. The total
number of emetic episodes (retching and vomiting) was recorded.
Thirty minutes after p.o. dosing with compound or vehicle control, the
ferrets were exposed to an aerosol of LPS (100 μg/mL) for 10 min.
Aerosols of LPS were generated by a nebulizer (DeVilbiss Healthcare,
Somerset, Pennsylvania), which was directed into the acrylic exposure
chamber. After a 10-minute exposure period, the animalswere returned
to the holding cages and allowed free access to water. The animals were
allowed access to food 60 to 90 min after p.o. dosing. Observation
continued for at least 2.5 h post-p.o. dosing, and emetic episodes
and behavioral changes were recorded. Six hours after LPS exposure,
the animals were killed by overdose of sodium pentobarbitone ad-
ministered intraperitoneally. Tracheae were then cannulated with
polypropylene tubing and lungs lavaged twice with 20 mL heparin-
ized (10 U/mL) PBS. The bronchoalveolar lavage samples were cen-
trifuged at 1500 rpm for 5 min. The supernatant was removed and
the resulting cell pellet was re-suspended in 1 mL PBS. A cell smear
of the re-suspended ﬂuid was prepared and stained with Leishman's
stain to allow differential cell counting. A total cell count was made
using the remaining re-suspended sample. From this, the total num-
ber of neutrophils in the bronchoalveolar lavage was determined.
The therapeutic index was calculated as the highest dose found to
not cause emetic episodes divided by the lowest dose found to inhib-
it pulmonary neutrophilia by ≥50%.Fig. 2. Lack of apremilast binding to cereblon, the molecular target of thalidomide.
A—Lenalidomide or apremilast was preincubatedwith humanmyeloma U266 cell extract
containing cereblon and then incubated with thalidomide analog afﬁnity beads. Beads
were washed and then bound proteins were eluted, subjected to SDS-PAGE, and
immunoblotted using an antibody against cereblon. In, input protein showing cereblon
presence in the cell lysate. B—Experiments were performed as in A using lenalidomide
and apremilast, and CRBN immunoblot band intensities were quantiﬁed. Data from two
independent experiments with samples from each experiment subject to two indepen-
dent immunoblots were used to calculate signal density relative to control density.3. Results
3.1. PDE selectivity
To determine the selectivity of apremilast among the various PDE
families, both cAMP- and cGMP-hydrolyzing activity of PDEs 1–11 was
tested. Several PDE4 isoforms were selected to represent the long
(4B1, 4C1), short (4B2, 4D2), and super-short (4A1A) isoforms [13].
PDE4B1, PDE4B2, PDE4D1, and PDE4D2 are reported to be expressed
in primary monocytes, macrophages, T cells, and neutrophils [41]. The
super-short PDE4A1 isoform is unique in that it contains an N-
terminal region that mediates its insertion into membranes and is
found enriched in Golgi and associated vesicles [42]. The PDE assays
conﬁrmed apremilast to be a selective inhibitor of PDE4,with signiﬁcant
inhibition observed only for the PDE4 isozymes. Apremilast (10 μM)
displayed an average of approximately 95% (range: 91%–99%) inhibition
of the PDE4 enzymes (A1A, B1, B2, C1, and D2) (Fig. 1). Apremilast did
not signiﬁcantly inhibit the other PDEs tested. Concentration-
dependent inhibition of these PDE4 isoforms was subsequently
conﬁrmed with apremilast IC50 values for PDE4A1A, PDE4B1, PDE4B2,
PDE4C1, and PDE4D2 of 14, 43, 27, 118, and 33 nM. This inhibition
pattern is consistent with the proﬁle of a pan-PDE4 inhibitor, with
some selectivity for the super-short PDE4A1A isoform.
Apremilast (10 μM) also did not signiﬁcantly inhibit any of the
255 kinases tested. Apremilast (10 μM) had no signiﬁcant activity
against any of the cell surface receptors or enzymes tested in a
broad-based screen, except for 95% inhibition of PDE4 (data not
shown).Apremilast has previously been referred to as a thalidomide analog
[43] because of their common structural feature, the phthalimide ring.
Recently, the molecular target of thalidomide has been identiﬁed as
cereblon, a component of an E3 ubiquitin ligase complex [39]. The bind-
ing of thalidomide to cereblon has been shown to be mediated through
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apremilast does not contain a glutarimide ring, itwould not be expected
to bind to cereblon. To conﬁrm this hypothesis, apremilast was tested
for cereblon binding afﬁnity. In cereblon competition binding experi-
ments, apremilast, at concentrations up to 100 μM, did not compete
for the binding of U266 multiple myeloma cell-derived cereblon with
the thalidomide analog afﬁnity beads. In contrast, preincubation with
lenalidomide did compete for cereblon binding, with approximately
50% inhibition at 3 μM (Fig. 2). These results demonstrate that
apremilast does not bind to human cereblon.
3.2. cAMP elevation
Apremilast elevated intracellular cAMP in PBMCs in response
to prostaglandin E2 in a manner similar to rolipram and cilomilast,
with a half-maximal effective concentration (EC50) of 1.4, 12, and 5 μM,
respectively (Fig. 3). However, roﬂumilast elevated cAMPmore potently
with an EC50 of 68 nM, and to a level approximately 50% higher than that
of rolipram. By contrast, thalidomide and its analogs, lenalidomide and
pomalidomide, did not increase intracellular cAMP levels at any concen-
tration up to 100 μM(Fig. 3), consistent with previous evidence showing
these compounds lack PDE4 inhibitory activity [45].
3.3. Cellular effects by innate and adaptive immune cells in vitro
To study the effects of apremilast on innate and adaptive im-
mune responses in vitro, and to compare it with the effects of the
thalidomide analogs lenalidomide and pomalidomide, four cell cul-
ture models were used: 1) LPS-stimulated PBMCs, to induce TNF-α
production via the TLR4 pathway in monocytes; 2) CpG
oligonucleotide-stimulated PBMCs, to induce interferon-α produc-
tion via the TLR9 pathway in plasmacytoid DCs; 3) B-cell stimula-
tion with cytokines, CD40 ligand, and CpG, to induce
differentiation and immunoglobulin secretion; and 4) CD3-
antibody stimulated T cells, to induce IL-2 and other cytokine pro-
duction. As previously reported, apremilast inhibited LPS-induced
TNF-α production, as did the thalidomide analogs lenalidomide
and pomalidomide, with an IC50 of 29 nM, 14 nM, and 2.7 nM, re-
spectively (Fig. 4A). However, in CpG oligonucleotide-stimulated
PBMCs, apremilast reduced interferon-α production with an IC50
of 0.62 μM, but lenalidomide had very modest effects, with only
28% reduction in interferon-α production at 10 μM (Fig. 4B).
When added to the B-cell differentiation culture, apremilast had a
modest effect on IgG production, with a maximal inhibition of
33% at 10 μM. By contrast, pomalidomide potently inhibited IgG
production with an IC50 of 63 nM (Fig. 4C). In the T-cell cultures,
apremilast inhibited IL-2 production with an IC50 of 2.4 μM, butFig. 3. Increase in intracellular cAMP levels by PDE4 inhibitors. Human PBMCswere pre-treated
was measured by immunoassay and normalized to the level induced by prostaglandin E2 in th
formed in duplicate.pomalidomide had the opposite effect, enhancing IL-2 production
by almost 20-fold (Fig. 4D). A selection of Th1, Th2, and Th17 cytokines
were also proﬁled in the T-cell cultures. Apremilast inhibited all T-cell-
derived cytokines with a range of potencies, including the Th2 cytokines
IL-5, IL-10, and IL-13with an IC50 in the 30 to 280 nM range, the Th17 cy-
tokine IL-17 with an IC50 of 90 nM, and the Th1 cytokines TNF-α, GM-
CSF, and interferon-γ with an IC50 in the 0.93 to 1.3 μM range (Fig. 5).
The least potent effect of apremilast was on the chemokine RANTES,
with an IC50 of 4.1 μM. Thus, while both apremilast and the thalidomide
analogs lenalidomide and pomalidomide can inhibit TLR4-dependent
TNF-α production, these two classes of compounds are quite distinct in
their effects on plasmacytoid DCs, B cells, and T cells.
To further explore the effects of apremilast and the thalidomide an-
alogs lenalidomide and pomalidomide on TLR4-dependent signaling,
gene expression proﬁling was conducted in puriﬁed monocytes stimu-
lated with LPS and analyzed on the GeneChip Human Genome U133A
array. Among the more than 39,000 transcripts represented on the
gene array, only 20 were regulated in common by all six compounds:
TNF, CCL8, P2RX7, FFAR2, VCAN, IL-12B, DENND2D, CXCL5, NBN,
CCL15, IL-23A, HDAC9, SPP1, TFPI, JAKMIP2, CDC42EP3, NCF1, DUSP6,
SGK, and RDH11 (Supplementary Table 1). Differences were clear be-
tween apremilast and the thalidomide analogs, with lenalidomide and
pomalidomide demonstrating a gene modulation pattern more similar
to each other than to apremilast (Fig. 6). The apremilast pattern was
more similar to that of roﬂumilast and cilomilast, while the c-Jun
N-terminal inhibitor produced a gene expression pattern unique to it-
self. In this study, apremilast modulated the expression of 498 genes
by ≥1.7-fold, and among the three PDE4 inhibitors, 239 genes were
regulated in common (Supplementary Table 2). An analysis of the
gene transcription, based on Gene Ontology and Broad MSigDB Canon-
ical Pathways, identiﬁed the top gene sets regulated concordantly by all
three PDE4 inhibitors as belonging to the immune response, inﬂamma-
tory response, cytokine activity, chemokine signaling, and stress re-
sponse biogroups (Table 1; Supplementary Table 3). In contrast, there
were numerous gene sets regulated by cilomilast and roﬂumilast, but
not by apremilast. The top gene sets reﬂecting this discordance among
the PDE4 inhibitors belonged to the cytoplasmic ribosome, peptide
chain elongation, ribosome, protein complex disassembly, and viral in-
fectious cycle biogroups (Table 2; Supplementary Table 3). Therefore,
while apremilast gene regulation was focused on the inﬂammatory
and immune response, cytokine and chemokine pathways, and
stress response genes, cilomilast and roﬂumilast exhibited a
broader pattern of gene regulation that included ribosomal genes,
protein translation and disassembly, and the viral response genes.
Conﬁrmatory studies using quantitative real-time polymerase
chain reaction analysis in LPS-stimulated monocytes found
that apremilast (1 μM) signiﬁcantly inhibited expression ofwith compounds for 1 h, then stimulatedwith prostaglandin E2 for 1 h. Intracellular cAMP
e presence of 100 μM rolipram. Results shown are the average of three experiments per-
Fig. 4. Effect of apremilast and thalidomide analogs on innate and adaptive immune cells. A—TNF-α production from LPS-stimulated human PBMCs. B—CpG oligonucleotide-stimulated
PBMCs. C—Effects of apremilast and pomalidomide on IgG secretion in normal PBMCs. Apremilast and pomalidomide + B-cell differentiating cocktail were added to normal PBMCs for
7 days. Cell culture supernatants were harvested and tested for human IgG by ELISA. The results were expressed as the percentage inhibition relative to control DMSO values and plotted
versus concentration of test compound. D—Effects of apremilast and pomalidomide on T-cell production of IL-2. IC50 values were calculated from the plots using non-linear regression,
sigmoidal-dose response constraining the top to 100% and bottom to 0% allowing for a variable slope. The data points represent the mean of three experiments. Error bars represent
the standard error of the mean.
2022 P.H. Schafer et al. / Cellular Signalling 26 (2014) 2016–2029interferon-γ by −8.64-fold (p b 0.01) and signiﬁcantly enhanced
expression of suppressor of cytokine signaling 3 (SOCS-3) by
2.23-fold (p b 0.01). In LPS-stimulated PBMCs, apremilast (1 μM)
signiﬁcantly inhibited expression of MCP-1 (CCL-2) by −5.04-
fold (p b 0.01), MCP-2 (CCL-8) by −21.3-fold (p b 0.001), MIP-4
(CCL-18) by −46.3-fold (p b 0.01), MIP-1αR (CCR-1) by −6.38-Fig. 5. Apremilast inhibition of Th1, Th2, and Th17 cytokines from primary human T cells stim
donors.fold (p b 0.05), interferon-γ by −15.2-fold (p b 0.05), and TNF-α
by −6.08-fold (p b 0.01), but signiﬁcantly up-regulated expres-
sion of amphiregulin by 2.07-fold (p b 0.05), bone morphogenic
protein 6 by −4.6-fold (p b 0.001), and the chemokine epithelial-
derived neutrophil-activating peptide 78 (CXCL-5) by 2.4-fold
(p b 0.05).ulated via anti-CD3 antibody. Results were averaged using data from four separate T cell
Fig. 6. Genome-wide gene expression analysis of LPS-stimulated primary human CD14+ monocytes treated with apremilast and the thalidomide analogs, lenalidomide and
pomalidomide. Affymetrix U133A gene chips representing approximately 13,000 unique human genes were used. RNA was pooled from four separate donors, and replicate gene chips
were run for each condition.
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The effects of apremilast were studied on Jurkat T cells and THP-1
monocytes in order to deﬁne the signaling pathways affected by PDE4 in-
hibition and cAMPelevation in immune inﬂammatory cells. Apremilast (1
and 10 μM),with andwithout forskolin 10 μM, signiﬁcantly induced CREB
phosphorylation at Ser133 in Jurkat T cells and, by contrast, roﬂumilast
had a modest increase that was not signiﬁcant (Fig. 7A). In THP-1Table 1
Top-scoring gene transcript biogroups regulated concordantly by PDE4 inhibitors in LPS-
stimulated monocytes.
Compound Common genes Direction p-Value Score
Immune response (GO) 118.14
Apremilast 45 ↓ 5.20E−16 35.20
Cilomilast 97 ↓ 5.60E−23 51.25
Roﬂumilast 36 ↓ 1.70E−14 31.70
Inﬂammatory response (GO) 82.73
Apremilast 27 ↓ 7.80E−15 32.49
Cilomilast 34 ↓ 9.80E−12 25.35
Roﬂumilast 26 ↓ 1.60E−11 24.89
Cytokine activity (GO) 67.70
Apremilast 20 ↓ 7.00E−14 30.30
Cilomilast 17 ↓ 3.90E−06 12.46
Roﬂumilast 15 ↓ 1.50E−11 24.94
Chemokine signaling (Broad MSigDB— canonical pathways) 64.62
Apremilast 13 ↓ 2.80E−11 24.31
Cilomilast 22 ↓ 6.20E−10 21.20
Roﬂumilast 14 ↓ 5.00E−09 19.10
Response to stress (GO) 64.52
Apremilast 72 ↓ 5.60E−09 19.00
Cilomilast 196 ↓ 1.70E−20 45.52
Roﬂumilast 71 ↓ 1.60E−07 15.64
LPS, lipopolysaccharide;MSigDB, Molecular Signatures Database.monocytic cells, apremilast showed a trend of increased CREB phosphor-
ylation, but the increase was not statistically signiﬁcant, while the PDE4
inhibitor roﬂumilast at 0.01 and0.1 μMsigniﬁcantly increasedCREBphos-
phorylation in THP-1 cells (Fig. 7B). Neither apremilast nor roﬂumilast
had a signiﬁcant effect on NF-κB nuclear localization in TNF-α-stimulated
Jurkat T cells (Fig. 7C) or LPS-stimulated THP-1 monocytes (Fig. 7D).
Upon phosphorylation of CREB/ATF-1, these transcription factors
bind to the cognate DNA sequence known as the cAMP responsiveTable 2
Top-scoring gene transcript biogroups regulated discordantly by apremilast versus other
PDE4 inhibitors in LPS-stimulated monocytes.
Compound Common genes Direction p-Value Score
Ribosome, cytoplasmic (Broad MSigDB—canonical pathways) 96.05
Apremilast 0 ns 0.00
Cilomilast 30 ↑ 1.30E−28 64.21
Roﬂumilast 22 ↑ 1.50E−14 31.84
Peptide chain elongation (Broad MSigDB—canonical pathways) 92.19
Apremilast 0 ns 0.00
Cilomilast 30 ↑ 1.30E−27 61.94
Roﬂumilast 22 ↑ 7.30E−14 30.25
Ribosome (Broad MSigDB—canonical pathways) 90.71
Apremilast 0 ns 0.00
Cilomilast 29 ↑ 1.00E−26 59.84
Roﬂumilast 22 ↑ 3.90E−14 30.87
Protein complex disassembly (GO) 86.74
Apremilast 0 ns 0.00
Cilomilast 30 ↑ 3.10E−25 56.43
Roﬂumilast 24 ↑ 6.90E−14 30.31
Viral infectious cycle (GO) 85.49
Apremilast 1 ↓ ns 1.69
Cilomilast 30 ↑ 1.40E−23 52.60
Roﬂumilast 25 ↑ 2.80E−14 31.21
LPS, lipopolysaccharide;MSigDB, Molecular Signatures Database.
Fig. 7. Effect of apremilast and roﬂumilast on CREB phosphorylation and NF-κB nuclear localization. A, B—Western blot analysis of CREB protein Ser133 phosphorylation in Jurkat T cells
(A) and THP-1 monocytic cells (B). A representativeWestern blot is presentedwith each graph. All treatment groupswere compared with DMSO by one-way ANOVA followed by Dunn's
Multiple Comparison Post-Test (n=5). No statistically signiﬁcant differencewas observed between apremilast and roﬂumilast. *pb 0.05 versusDMSO, **p b 0.01 versusDMSO, 30-minute
stimulationwith drug. C, D—Westernblot analysis of NF-κB nuclear localization in Jurkat T cells stimulatedwith TNF-α over 1 h (C) and THP-1monocytic cells stimulatedwith LPS over 1 h
(D). A representativeWestern blot is presented alongwith each graph. Treatment groupswere compared with TNF-α or LPS by one-way ANOVA followed by Dunnett's multiple compar-
ison post-test (n = 3). No statistically signiﬁcant difference was observed between apremilast and roﬂumilast or any other group.
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Apremilast concentrations of 0.1, 1, and 10 μM signiﬁcantly enhanced
CRE-driven transcriptional activity in Jurkat T cells (Fig. 8A) and THP-1
monocytes (Fig. 8B) at 6 h. At the same time, apremilast signiﬁcantly
inhibited NF-κB-driven transcriptional activity at 0.1, 1, and 10 μM in
both Jurkat (Fig. 8C) and THP-1 (Fig. 8D) cell lines.3.5. Adaptive immune responses: antigen-speciﬁc transgenic T- and B-cell
clonal expansion mouse model
To study the effect of apremilast on the adaptive immune responses
(i.e., antigen-speciﬁc clonal expansion and activation of T cells and B
cells), the OVA-speciﬁc KJ1.26+ T-cell and HEL-speciﬁc IgMa+ B-cell
transfer mouse model was used. In this model, these transgenic T and
B cells were transferred intravenously into a recipient mouse strain,
and the conjugated peptide antigen OVA-HEL was injected subcutane-
ously, with or without treatment with apremilast (5 mg/kg/day). This
dosewas similar to the dose used to demonstrate an anti-psoriatic effect
in a xenograft mouse model [15], and much greater than the doses
required to inhibit LPS-induced blood TNF-α levels in the rat (half-
maximal effective dose [ED50] 0.03 mg/kg), or to inhibit LPS-induced
lung neutrophilia in the rat (ED50 0.3 mg/kg) [18].Clonal expansion of KJ1.26+ T cells in the OVA-HEL immunized
mice treated with vehicle control was ﬁrst observed at Day 3 and
continued through Day 5 to peak at 5% of lymphocytes on Day 7
(Fig. 9A). On each day after Day 2, the percentage of KJ1.26+ T cells
was signiﬁcantly higher in the OVA-HEL immunized group than in the
unimmunized group (p b 0.05). Treatment with apremilast did not
affect this clonal expansion of the KJ1.26+ T cells at any time point
(Fig. 9A).
The percentage of IgMa+ B cells increased steadily during the ex-
periment in OVA-HEL immunized mice treated with either apremilast
or vehicle (Fig. 9B). These cells constituted approximately 1.5% of the
lymphocytes at the beginning of the study and ﬁnished at approximate-
ly 2%. On Days 5, 7, and 10, the percentage of IgMa+ B cells in
immunized mice was signiﬁcantly higher than in unimmunized mice
(p b 0.05). Apremilast had no effect on the number of IgMa+ B cells
at any of these time points (Fig. 9B).
Expression of the T-cell activation marker CD69 was detected upon
80% of KJ1.26+ T cells in OVA-HEL immunized mice treated on Day 2,
but on only 25% of unimmunized mice (p b 0.05) (Fig. 9C). This CD69
expression was not affected by apremilast in either the immunized or
unimmunized animals. Approximately 45% of KJ1.26+ T cells in OVA-
HEL immunized mice expressed the T-cell activation marker CD25 on
Day 2, compared with only 3% of KJ1.26+ T cells from unimmunized
Fig. 8.A, B—Effect of apremilast on CRE-driven transcription in Jurkat T cells (A) and THP-1monocytic cells (B) at 6 h. All treatment groupswere comparedwith DMSOby one-wayANOVA
followed byDunnett'sMultiple Comparison Post-Test (n=4); *p b 0.05; **p b 0.01, ***p b 0.001. C, D—Effect of apremilast onNF-κB-driven transcriptional activity in Jurkat T cells (C) and
THP-1 monocytic cells (D) at 6 h. All treatment groups were compared with TNF-α (C) or LPS (D) by one-way ANOVA followed by Dunnett's multiple comparison post-test (n =
4); ***p b 0.001 versus TNF-α or LPS.
2025P.H. Schafer et al. / Cellular Signalling 26 (2014) 2016–2029mice (p b 0.05) (Fig. 9C). Apremilast had no signiﬁcant effect on CD25
expression in either immunized or unimmunized mice. The T-cell
activation marker CD62L, which typically decreases on activated cells,
was reduced by immunization on Day 3 from 79% to 63%, although
this decrease was not signiﬁcant. In the immunized apremilast-treated
group, CD62L expressionwasmaintained at 79%, whichwas signiﬁcant-
ly higher than in the immunized vehicle control group. Therefore, a de-
crease in CD62L did not occur in the apremilast-treated immunized
animals (Fig. 9C). Following restimulation of lymphocytes with OVA
on Day 10, apremilast did not affect T-cell proliferation or interferon-γ
production (data not shown).
For the B-cell activation marker CD80, no signiﬁcant differences in
the percentage of CD80high Tg IgMa+ B cells were noted on Day 3 and
Day 5 between any of the treatment groups. On Day 7, the peak of
CD80 expression, the unimmunized groups had signiﬁcantly fewer
CD80high Tg IgMa+ B cells than the immunized group treated with
apremilast, but not the immunized control group. No signiﬁcant differ-
ence in CD80 expression in the immunized mice was noted between
apremilast and vehicle treatment (Fig. 9D). For CD86, on Day 3, signiﬁ-
cant differenceswere only encountered in the percentage of CD86high Tg
IgMa+ B cells between unimmunized mice treated with either vehicle
or apremilast and immunized mice treated with apremilast (p b 0.05).
The immunized control was not signiﬁcantly greater than the unimmu-
nized control. On Day 5, the peak of CD86 expression, CD86high Tg
IgMa+ B cells were observed to be higher in immunized groups
compared with unimmunized groups (p b 0.05), but no signiﬁcant
differences were observed in immunized mice when comparing
apremilast and vehicle treatment (Fig. 9D). By Day 7, statistically signif-
icant differences were only observed when comparing unimmunized
vehicle-treated mice and immunized mice treated with either vehicle
or apremilast (p b 0.05). For CD40, on Day 3 signiﬁcant differences inthe percentage CD40high IgMa+ B cell populations were observed
between unimmunized mice treated with vehicle and immunized
mice treated with either vehicle or apremilast (p b 0.05). No signiﬁcant
differences were observed between unimmunized mice treated with
apremilast and immunized mice treated with vehicle or apremilast,
nor were there signiﬁcant differences between immunized control-
treated mice and their counterparts treated with apremilast. On Day 5,
there were no signiﬁcant differences between any of the treatment
groups. On Day 7, the peak of CD40 expression, signiﬁcant differences
were encountered for unimmunized mice treated with vehicle and im-
munized mice treated with vehicle, but apremilast had no effect on
CD40 expression (Fig. 9D). Overall, apremilast had no signiﬁcant effect
on CD80, CD86, or CD40 expression on IgMa+ B cells on any day in
the immunized mice compared with the immunized vehicle-treated
mice. Production of OVA-speciﬁc IgG1, OVA-speciﬁc IgG2a, or
HEL-speciﬁc IgMa was not affected by apremilast (data not shown).
3.6. Innate immune response and therapeutic index calculation: ferret lung
neutrophilia versus gastrointestinal side effects
The conscious ferret model has been used to investigate anti-
inﬂammatory, emetic, and behavioral effects of PDE4 inhibitors when
administered by the oral route. Following apremilast dosing, signiﬁcant
(p b 0.05) inhibition of the lung neutrophilia was observed at 1, 10, and
30 mg/kg (62%, 70%, and 77%, respectively; Fig. 10A). Following
compound dosing, the ferrets were observed for at least 2 h, and emetic
episodes (retching and vomiting) and behavioral changes were record-
ed. Apremilast at doses b10 mg/kg caused no emetic episodes (retching
and vomiting). Some behavioral changes (ﬂattened posture, lip licking,
and backward walking) were observed and classiﬁed as mild. At
10 mg/kg in two of six ferrets, some retching but no frank emesis was
Fig. 9. A—T-cell expansion, as shown by percentage of KJ1.26+ cells in lymph nodes. B—B-cell expansion, as shown by percentage of IgMa + cells in lymph nodes. C—T-cell activation
markers on KJ1.26+ cells. *p b 0.05 between the groups. D—Expression of B-cell activation markers on IgMa + cells. *p b 0.05 between the groups. Data points and bars represent the
mean and standard error of the mean from ﬁve animals per time point.
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or moderate), yielding an average of 0.5 episodes per animal. At the
highest dose tested (30 mg/kg), moderate to marked emesis was
observed in three of four animals along with pronounced behavioral
changes. By comparison, cilomilast signiﬁcantly inhibited lung neutro-
phils at 10 mg/kg by 51% (p b 0.05) (Fig. 10B). Regarding the number
of emetic episodes, cilomilast induced retching and vomiting at doses
of 3 to 10 mg/kg. From these experiments, a therapeutic index was de-
termined by dividing the threshold dose for inducing emetic episodes
by the ED50 value for inhibiting the pulmonary neutrophilia. The thera-
peutic index values are summarized in Table 3. Of the compoundsFig. 10. Ferret lung neutrophilia and emesis model results with apremilast and cilomilast. *p b
eight animals.evaluated, apremilast had the higher therapeutic index (12), causing
no emetic episodes at an anti-inﬂammatory dose of 1 mg/kg. Cilomilast,
by comparison, had a therapeutic index b1 (0.38), indicating a 30-fold
improvement in therapeutic index for apremilast compared with
cilomilast.
4. Discussion
Apremilast is a PDE4 inhibitor that helps regulate the immune re-
sponse that causes inﬂammation associated with PsA and psoriasis. In
the current report, enzyme assays conﬁrm that apremilast is a speciﬁc0.05 for inhibition of lung neutrophilia. Data are the mean ± standard error from four to
Table 3
Therapeutic index for apremilast and cilomilast based on inhibition of neutrophilia and
emetic dose in the ferret.
Compound Inhibition of LPS-induced
neutrophilia
(ED50 mg/kg)
Threshold emetic dose
(mg/kg)
Therapeutic
index
Apremilast 0.8 10 12
Cilomilast 8 3 0.38
ED50, dose producing a response that is 50% of the maximum obtainable.
Table 4
Comparison of structural and pharmacological differences between apremilast and
thalidomide and the IMiDs® compounds, lenalidomide and pomalidomide.
Apremilast Thalidomide, lenalidomide,
and pomalidomide 
Thalidomidea
Key chemical group Dialkoxyphenyl ring (blue) Amino–glutarimide ring (red) 
NoYesPDE4 binding
NoYesIncrease in cyclic AMP
NoYesInhibit T and NK cells
YesNoCereblon binding
YesNoInhibit B cells
YesNoCo–stimulate T and NK cells
aAmino–glutarimide ring (red) of the thalidomide structure is also part of the structure of 
lenalidomide and pomalidomide. 
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of PDE4, apremilast did not signiﬁcantly inhibit any of the kinases tested
andhadno signiﬁcant activity against any of the cell surface receptors or
enzymes tested. Therefore, the only known molecular targets of
apremilast are the PDE4 family of enzymes.
Apremilast is able to potently bind and inhibit PDE4 because it con-
tains the dialkoxyphenyl pharmacophore [18]. The dialkoxyphenyl
group is found in several other PDE4 inhibitors,which have been clinical-
ly tested or are approved [46–48]. By contrast, thalidomide and its
functional analogs, the IMiDs® compounds, lenalidomide and
pomalidomide, bind to cereblon, an E3 ubiquitin ligase substrate co-
receptor protein encoded by the gene CRBN [39,44]. Cereblon has been
shown to mediate the antiproliferative effect of lenalidomide and
pomalidomide against multiple myeloma cells, as well as their T-cell
co-stimulatory effects [44]. Also, in embryonic development models
using zebraﬁsh and chick embryos, cereblon bindingwas found tomedi-
ate the teratogenic effects of thalidomide [39]. The key pharmacophore
for thalidomide, lenalidomide, and pomalidomide is the glutarimide
ring; this ring mediates the binding of thalidomide, lenalidomide, and
pomalidomide to cereblon [39,44]. Because apremilast does not contain
a glutarimide ring, the inability of apremilast to bind to cereblon
(Fig. 2) was an expected result.
Apremilast also contains another chemical group, the isoindolinone
group (also known as the phthalimide group) [18]. This phthalimide
group does not control binding to cereblon [39,44]. Before the discovery
of cereblon, the molecular mechanism of action of thalidomide was not
known, and it was not knownwhich part of themolecule was responsi-
ble for its pharmacological function. Thus, in older publications, com-
pounds containing the phthalimide group were sometimes referred to
as “thalidomide analogs” [49]. Since it is now understood that thalido-
mide binding to cereblon is mediated through the glutarimide ring
[39,44], apremilast is no longer considered to be a functional analog of
thalidomide.
In addition to having a different structure and function than thalido-
mide, lenalidomide, and pomalidomide, apremilast also has very differ-
ent pharmacological effects in cells. For example, while thalidomide and
its analogs, lenalidomide and pomalidomide, enhance the activity of T
cells [45] and NK cells [50], apremilast has the opposite effect, and it ac-
tually inhibits the cytokine production by T cells (Figs. 4 and 5) and NK
cells [15]. A summary of the structural and pharmacological differences
between apremilast and the thalidomide analogs is provided in Table 4.
The immunopathophysiology of inﬂammatory diseases such as pso-
riasis and arthritis is complex, involving cells of both the innate immune
system, such asmonocytes andDCs, and the adaptive immune provided
byT cells andB cells [1,2]. PlasmacytoidDCs are key sentinels that,when
activated through TLR ligands, produce the type 1 interferon-α,
resulting in myeloid DC and T-cell activation [1–3,51]. Apremilast
10 μM efﬁciently inhibited interferon-α by TLR9 ligand-stimulated
PBMCs by approximately 75%. These ﬁndings are consistent with previ-
ous reports that apremilast suppresses expression of MX1 mRNA, a
marker of the type 1 interferon response in skin lesions from patients
enrolled in an open-label phase II apremilast study in recalcitrant psori-
asis [24]. Another notable observation in the current study is the inhibi-
tion of IL-17 production by puriﬁed T cells (IC50 90 nM) (Fig. 5). This,
too, was conﬁrmed in the recalcitrant psoriasis study, wherein
apremilast treatment resulted in a median 72.5% reduction of IL-17AmRNA in skin lesions after 4 weeks [24]. This direct inhibition of IL-17
production is important, given the crucial role that Th17 cells play in
the pathophysiology of psoriasis [52].
Differentiation of B cells to antibody-producing plasma cells is an-
other important component of the autoimmune and inﬂammatory re-
sponses in diseases such as rheumatoid arthritis [53]. Our study
demonstrated that the effects of apremilast on B-cell differentiation
are weak. Apremilast did not signiﬁcantly inhibit IgG (Fig. 4C) or IgM
production (data not shown) in normal B-cell differentiation cultures.
This ﬁnding suggests that the effects of apremilast on adaptive immuni-
ty may be minor, especially compared with the reduction of innate im-
mune responses seen against monocytes, neutrophils, and NK cells [15].
Indeed, this observation was conﬁrmed in vivo using the antigen-
speciﬁc mouse B-cell transfer model, wherein no effects of apremilast
on B-cell activation were observed (Fig. 9).
In the gene chip analysis, clear differences in gene expression were
noted between apremilast and the thalidomide analogs, lenalidomide
and pomalidomide. Gene expression studies in LPS-stimulated human
PBMCs and monocytes identiﬁed several targets of gene regulation by
apremilast, including the inhibition of many chemokines, chemokine
receptors, and Th1 cytokine genes, as well as enhancement of the
genes encoding the anti-inﬂammatory factor SOCS-3. SOCS-3 is an in-
hibitor of the cytokine receptor/JAK-STAT pathway and has previously
been observed to be induced by cAMP elevation via the activation of
Epac1 (exchange protein directly activated by cAMP 1) [54]. Thus,
apremilast may be able to suppress cytokine signaling through the IL-
6 and other class I cytokine receptors, through activation of Epac1, ex-
pression of SOCS-3, and inhibition of JAK-STAT signaling.
Through increases in intracellular cAMP, PDE4 inhibitors lead to
phosphorylation and activation of PKA [15]. This results in up-
regulation of CREB and down-regulation of NF-κB-dependent genes
[14,15]. The current data from Western blot analyses show that
apremilast signiﬁcantly induces CREB phosphorylation, which is indica-
tive of PKA activation. Apremilast signiﬁcantly enhanced CRE-driven
gene transcription in Jurkat T cells and THP-1 monocytic cells, which
can subsequently induce transcription of genes such as IL-10 and IL-6
[15]. Theseﬁndings are consistentwith CREB phosphorylation observed
byWestern blot and conﬁrm that apremilast activates the PKA pathway
in these cells. In addition, apremilast inhibits NF-κB transcriptional ac-
tivity, which drives expression of genes such as TNF-α [15]. The
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activity of NF-κB is mediated either by a competition for CREB-binding
protein [55], or via a direct or indirect modiﬁcation of the C-terminal
transactivation domain of NF-κB p65 [56]. Our studies show that
apremilast does indeed induce phosphorylation of the PKA substrates
CREB and ATF-1, induce CRE-dependent transcriptional activity, and in-
hibit NF-κB transcriptional activity without affecting nuclear transloca-
tion of NF-κB. These data are consistent with either the CREB-binding
protein-dependent or CREB-binding protein-independent model of
NF-κB inhibition. Interestingly, our results suggest that there may be
differences between apremilast and roﬂumilast with respect to CREB
phosphorylation in Jurkat T cells and THP-1 monocytic cells; these po-
tential distinctions are being explored further in additional studies.
5. Conclusions
The current analyses conﬁrm that apremilast is a selective inhibitor
of PDE4 that works intracellularly to regulate inﬂammatory mediators.
Apremilast activates the PKA-CREB/ATF-1 pathway, resulting in
enhancement of CRE-driven gene transcription and inhibition of NF-
κB-driven gene transcription. Unlike thalidomide or its analogs,
lenalidomide and pomalidomide, apremilast does not bind to human
cereblon and shows clear differences from these drugs in cellular
pharmacology and gene expression studies. Unlike pomalidomide,
apremilast showed minimal effects on B-cell differentiation and immu-
noglobulin production, supporting previous ﬁndings that the effects of
apremilast on innate immunity are greater than those on adaptive im-
munity. Despite having an inhibitory effect on Th1, Th2, and Th17 cyto-
kine production, there was no effect of apremilast on T-cell or B-cell
clonal expansion (Fig. 9), or on antibody responses in vivo (data not
shown). These ﬁndings may explain the low risk of serious infection
and overall safety proﬁle reported in clinical studies to date [20,25,26,
57]. Long-term use of currently available non-biologic and biologic
systemic therapies is often compromised by adverse events, safety and
tolerability issues, loss of effect over time, and administration by injec-
tion [3,58]. Treatment options are needed that are efﬁcacious, safe,
well tolerated, and easy to use. In the ferret pharmacology/tolerability
model measuring an innate immune response and the known PDE4
inhibitor-mediated gastrointestinal side effects (nausea and vomiting),
apremilast demonstrated a signiﬁcant anti-inﬂammatory effect with a
N10-fold margin compared with the onset of side effects, representing
a 30-fold improvement over cilomilast, another PDE4 inhibitor that
had been previously been in clinical development. These nonclinical
pharmacology and tolerability results provide support regarding why
apremilast may represent an important new oral treatment option for
patients with inﬂammatory conditions.
In phase III studies, apremilastwas effective andwell tolerated in the
treatment of psoriasis and PsA [29–33]. In the ESTEEM 1 study,
apremilast signiﬁcantly improved Psoriasis Area and Severity Index
scores in patients with moderate to severe plaque psoriasis; after
16 weeks, a signiﬁcantly greater proportion of patients receiving
apremilast 30 mg BID (33%) achieved a 75% reduction from baseline
Psoriasis Area and Severity Index score compared with those receiving
placebo (5%; p b 0.0001 versus placebo) [29]. In the PALACE 1 study
(the ﬁrst study from the PALACE clinical trial program), patients with
active PsA achieved 20% improvement in modiﬁed American College
of Rheumatology response criteria at 16 weeks at a signiﬁcantly greater
rate with apremilast 20 mg BID (31%; p b 0.02) and apremilast 30 mg
BID (40%; p = 0.0001) compared with placebo (19%) [30]. In a pooled
safety analysis of the PALACE 1, PALACE 2, and PALACE 3 studies, the
most common adverse events were diarrhea, nausea, headache, upper
respiratory tract infection, and nasopharyngitis [59]. Most adverse
events were mild to moderate in severity, and discontinuations due to
adverse events were low [59]. In addition, no relevant safety signals
for opportunistic infection, cancer, demyelination, or lupus-like syn-
dromes have been attributed to apremilast to date. There also havebeen no indications of signiﬁcant laboratory or electrocardiographic ab-
normalities or clinically signiﬁcant effects on liver function, white blood
cells, blood pressure, or hemoglobin. Additional results from the
PALACE 2, PALACE 3, and PALACE 4 studies demonstrate the clinical
efﬁcacy of apremilast in patients with active PsA, with no new safety
signals observed and improved tolerability over phase II studies [27,
31–33,60].
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2014.05.014.
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